Impact of 68Ga-PSMA PET/CT on radiation treatment planning of prostate cancer patients

Abstract

Abstract Aim This study aimed to assess the impact of 68Ga-PSMA PET/CT on radiation treatment (RT) planning in prostate cancer patients with salvage (sRT) or definitive (dRT) radiotherapy. Methods 38 patients (27 sRT, median PSA 0.79 ng/ml (range 0.06–12.1); 11 dRT, median PSA 4.35 ng/ml (range 1.55–55.5) underwent 68Ga-PSMA PET/CT before RT. Influence of 68Ga-PSMA PET/CT on the extent of planning target volume (PTV) and addition of PET-based boosts were assessed. Median follow up was 12 months (range 3–24). Results 68Ga-PSMA PET/CT showed positive findings in 23/38 patients (8/23: local recurrence (LR), 11/23: nodal metastasis, 1/23: LR and nodal, 2/23: solitary bone metastasis, 1/23: oligometastatic nodal/ bone metastases). In sRT primary PTV was changed in 16/27 patients extending the PTV to the lymphatic drainage (10/16), PSMA-positive LR (3/16), bone metastases (2/16) and both nodal/bone metastases (1/16). PET-based increase of primary PTV was 116%. PET-based boosts were administered in 19/27 patients (8/19: local, 10/19: nodal, 1/19: both), median boost volume was 31.3 cm3 (range 17.2–80.2) (local) and 19.7 cm3 (range 3.0–109.3) (nodal). PTV was changed in 1/11 (9%) of dRT patients (extension of primary PTV to the lymphatic drainage (RT volume of 644.5 cm3), additional nodal boost (volume of 2.7 cm3, 23.1 Gy)). All patients showed biochemical response (mean PSA decrease 88.8 +/– 14.0%). Nadir PSA was reached 10 months (range 1–17) after end of RT (median 0.07 ng/ml, range 0.002–3.96). Within a median 12 months follow-up (range 3–22/8–24 in sRT/dRT), median PSA was 0.05 ng/ml (range 0.002–8.5) (sRT) and 0.26 ng/ml (range 0.02–2.68) (dRT). Conclusions 68Ga-PSMA PET/CT influenced sRT planning in almost 63% and dRT in 9% of patients by change of PTV and additional boosts.